2016 Jun 21. doi: 10.18632/oncotarget.10206. [Epub ahead of print]
Andradas C1,2, Blasco-Benito S1,2, Castillo-Lluva S1, Dillenburg-Pilla P3, Diez-Alarcia R4, Juanes-García A5, García-Taboada E1, Hernando-Llorente R1, Soriano J6, Hamann S7, Wenners A7, Alkatout I7, Klapper W8, Rocken C8, Bauer M7, Arnold N7, Quintanilla M9, Megías D6, Vicente-Manzanares M5, Urigüen L4, Gutkind JS3,10, Guzmán M1,11, Pérez-Gómez E1,2, Sánchez C1,2.
Abstract
The orphan G protein-coupled receptor GPR55 has been directly or indirectly related to basic alterations that drive malignant growth: uncontrolled cancer cell proliferation, sustained angiogenesis, and cancer cell adhesion and migration. However, little is known about the involvement of this receptor in metastasis. Here, we show that elevated GPR55 expression in human tumors is associated with the aggressive basal/triple-negative breast cancer population, higher probability to develop metastases, and therefore poor patient prognosis. Activation of GPR55 by its proposed endogenous ligand lysophosphatidylinositol confers pro-invasive features on breast cancer cells both in vitro and in vivo. Specifically, this effect is elicited by coupling to Gq/11 heterotrimeric proteins and the subsequent activation, through ERK, of the transcription factor ETV4/PEA3. Together, these data show that GPR55 promotes breast cancer metastasis, and supports the notion that this orphan receptor may constitute a new therapeutic target and potential biomarker in the highly aggressive triple-negative subtype.
KEYWORDS:
G protein-coupled receptor; GPR55; cannabinoids; metastasis; triple-negative breast cancer
- PMID: 27340777
- [PubMed – as supplied by publisher]